ClinicalTrials.gov
public full text
Public Domain
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are unable to receive standard treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors#884305
- A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors#827498
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours#1085611
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS#1030131
- A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors#994207
Record · ID 856923
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive